KLP Kapitalforvaltning AS Purchases New Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

KLP Kapitalforvaltning AS bought a new position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 15,100 shares of the life sciences company's stock, valued at approximately $342,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its holdings in shares of Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after purchasing an additional 2,800 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Integra LifeSciences by 33.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 19,755 shares of the life sciences company's stock worth $448,000 after buying an additional 4,967 shares during the last quarter. Nordea Investment Management AB grew its position in Integra LifeSciences by 4.1% during the fourth quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company's stock valued at $2,919,000 after acquiring an additional 5,032 shares during the last quarter. Choreo LLC raised its stake in shares of Integra LifeSciences by 29.9% during the fourth quarter. Choreo LLC now owns 22,274 shares of the life sciences company's stock worth $500,000 after acquiring an additional 5,123 shares in the last quarter. Finally, Empowered Funds LLC bought a new stake in shares of Integra LifeSciences in the 4th quarter worth approximately $180,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $23.00.

Integra LifeSciences Trading Down 9.2 %

NASDAQ IART traded down $1.77 on Thursday, hitting $17.42. The company's stock had a trading volume of 632,035 shares, compared to its average volume of 1,049,451. The firm has a market cap of $1.35 billion, a P/E ratio of -193.53, a PEG ratio of 0.73 and a beta of 1.24. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $34.41. The company's 50-day simple moving average is $22.46 and its 200 day simple moving average is $22.31. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. The company had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm's revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.89 earnings per share. Research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.